Sarepta Therapeutics Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company has classified its drug development programs as Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs. The Company�s Duchenne muscular dystrophy (DMD) is primarily focused on its lead product candidate, Eteplirsen. The Company has completed a Phase IIb clinical trial for Eteplirsen. The Company, under its infectious disease programs, is primarily focused on development of a drug candidate for the Marburg hemorrhagic fever virus. The Company�s infectious disease programs is largely funded and supported by the U.S. Department of Defense (DoD).